Catalytic Health

*Comparative clinical significance unknown. A prescription second-generation, antihistamine with a unique dual mode of action of: Histamine H1-Receptor Antagonist Platelet Activating Factor Receptor Antagonist. 1 * Over 2.5 billion tablets sold worldwide 2 Chronic spontaneous urticaria: Rupall is indicated for the relief of the symptoms associated with chronic spontaneous urticaria, e.g. pruritus and hives, in patients 2 years of age and older. *Comparative clinical significance unknown. Allergic rhinitis: Rupall is indicated for the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older. Rupall TM is a trademark from Uriach, Spain Clinical use: Geriatrics (>65 years of age): higher sensitivity of some older individuals cannot be excluded. Pediatrics (2-11 years of age): 10 mg tablets not recommended. Pediatrics (<2 years of age): RUPALL has not been studied in children <2 years of age. RUPALL should not be administered in children <2 years of age. Contraindications: • Hypersensitivity to rupatadine or to any ingredient in the formulation or component of the container. • History of QT prolongation and/or torsade de pointes, including congenital long QT syndromes, history of cardiac arrhythmias. • Use of CYP3A4 inhibitors or use of other QTc-prolonging drugs. • With galactose intolerance, glucose-galactose malabsorption or the Lapp lactase deficiency (tablets only) and with rare hereditary problems of fructose intolerance, glucose/galactose malabsorption or sucrase isomaltase insufficiency (solution only). Relevant warnings and precautions: Caution should be taken when Rupall is co-administered with drugs with narrow therapeutic windows since knowledge of the effect of Rupall on other drugs is limited. • Rupall has no influence on ability to drive and use machinery. Nevertheless, care should be taken before driving or using machinery until the patient's individual reaction on rupatadine has been established. • Use in patients with impaired liver or renal function is not recommended. • Although rare, hypersensitivity reactions have been reported in post-marketing experience with RUPALL 10 mg tablets. • Effects on skeletal muscle been reported in patients. • RUPALL Oral Solution contains methyl parahydroxybenzoate as a preservative. • Use in pregnant or nursing women not recommended. • Increases of blood creatine phosphokinase, alanine aminotransferase and aspartate aminotransferase, as well as abnormalities of liver function tests were uncommonly reported • Use with caution in elderly patients (65 years and older). Although no overall differences in effectiveness or safety were observed in clinical trials, higher sensitivity of some older individuals cannot be excluded. For more information: Please consult the product monograph https://health-products.canada.ca/dpd-bdpp/index- eng.jsp for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The product monograph is also available by calling us at 1-877- 630-5674. References: 1. Rupall Product Monograph, Pediapharm Inc. January 3, 2017. 2. Data on file. Rupall 10mg and Oral Solution - Convenient once-daily dosing taken with or without food. 1 Rupall is indicated for: 1

• Cover